Quick View
| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥47.6B | ¥42.3B | +12.6% |
| Operating Income / Operating Profit | −¥11.4B | −¥13.7B | +16.6% |
| Profit Before Tax | −¥12.0B | −¥14.3B | +16.1% |
| Net Income / Net Profit | −¥8.5B | −¥10.3B | +17.3% |
| ROE | −1.7% | −2.0% | - |
Executive Summary
FY2026 Q1 results: Revenue ¥47.6B (YoY +¥5.3B +12.6%), operating loss ¥11.4B (YoY improved by ¥2.3B, loss narrowed by 16.6%), ordinary loss ¥12.2B (YoY improved by ¥2.3B, loss narrowed by 16.1%), net loss ¥8.5B (YoY improved by ¥1.8B, loss narrowed by 17.3%). The Radiopharmaceuticals Business accounted for 85.9% of revenue and drove a YoY increase of +7.0%, while the Drug Discovery & Development Business recovered sharply with +64.6%. Gross margin improved materially to 42.6% (from 34.7% a year earlier, +7.9pp) as manufacturing efficiency and product mix improved. R&D expenses remained heavy at ¥12.3B (25.8% of revenue), and operating losses continued. Net loss was mitigated by tax benefits of ¥3.5B, showing improvement YoY. Cash balance ¥255.5B, interest-bearing debt ¥163.4B, resulting in net cash approx. ¥92B. Short-term borrowings were significantly reduced from ¥170.4B to ¥26.1B with refinancing into long-term borrowings of ¥137.3B, improving financial stability. Operating Cash Flow was negative ¥9.5B but markedly improved from ¥-98.3B a year earlier. Against full-year plan (Revenue ¥320.0B, Operating Income ¥46.0B), Q1 progress is weak at 14.9% of revenue; recognition of milestones from Q2 onward and segment margin improvements will be key to achieving targets.
Drivers of Performance
[Revenue] Revenue was ¥47.6B, up ¥5.3B YoY (+12.6%). Core Radiopharmaceuticals Business external sales were ¥40.9B (prior year ¥38.3B, +7.0%), accounting for 85.9% of total revenue, supported by expanding diagnostic and therapeutic radiopharmaceutical demand and scale effects. Drug Discovery & Development external sales surged to ¥6.7B (prior year ¥4.1B, +64.6%), driven by technology licensing and progress in co-development agreements. Including inter-segment sales, Radiopharmaceuticals totaled ¥43.4B (prior year ¥40.1B) and Drug Discovery & Development ¥6.7B (prior year ¥4.1B). Although regional/product breakdown is not disclosed in detail, company-wide 12.6% growth is estimated to reflect both diagnostic demand and progress in discovery partnerships.
[Profitability] Cost of sales was ¥27.4B (prior year ¥27.6B), nearly flat, and gross profit jumped to ¥20.3B (prior year ¥14.7B, +38.1%), with gross margin improving to 42.6% (from 34.7%, +7.9pp). Manufacturing efficiency and product mix improvements boosted gross margin. SG&A was ¥19.3B (prior year ¥18.4B, +4.6%), and R&D was ¥12.3B (prior year ¥9.9B, +24.6%), reflecting front-loaded investment in drug discovery. Operating loss was ¥11.4B (prior year ¥13.7B), narrowing by ¥2.3B as gross margin improvement absorbed higher expenses. Financial income ¥0.9B and financial expenses ¥1.6B produced net financial expense of ¥-0.6B (almost unchanged from prior year ¥-0.6B). Equity-method loss ¥0.0B added to ordinary loss of ¥12.2B (prior year ¥14.3B). Other income/expenses were net ¥-0.1B and extraordinary items were negligible, resulting in loss before tax of ¥12.0B (prior year ¥14.3B). Income tax benefit was ¥3.5B (prior year ¥4.0B benefit), aided by restrained derecognition of deferred tax assets, leading to net loss of ¥8.5B (prior year ¥10.3B). In summary, this quarter was characterized by revenue growth and reduced losses (narrowing of deficits), with an ongoing tug-of-war between gross margin improvement and front-loaded expenditure.
Segment Analysis
Radiopharmaceuticals Business: Revenue ¥40.9B (prior year ¥38.3B, +7.0%), operating income ¥0.7B (prior year ¥0.8B, -10.7%) implying a margin of 1.8%. Demand for diagnostic and therapeutic radiopharmaceuticals is healthy, but extremely thin margins indicate a heavy cost structure. Including inter-segment sales, total for the segment was ¥43.4B (prior year ¥40.1B), reflecting expanded intra-group supply and higher manufacturing capacity utilization, though fixed-cost absorption remains limited. Drug Discovery & Development: Revenue ¥6.7B (prior year ¥4.1B, +64.6%), but operating loss ¥11.9B (prior year ¥14.3B), loss narrowed by 16.5%, with a margin of -177.9%, indicating severe losses. The burden of front-loaded R&D spending is significant; milestone and license revenue timing creates high volatility. Adjustment items include business combination related expenses (amortization of intangible assets) ¥0.2B, leaving consolidated operating loss at ¥11.4B. Improvement in Radiopharmaceuticals margins and turning Drug Discovery & Development to profitability are essential for consolidated profitability improvements.
Key Financial Metrics
[Profitability] Operating margin was -23.9% (prior year -32.3%), narrowing but still severe. Gross margin improved materially to 42.6% (from 34.7%, +7.9pp), reflecting manufacturing efficiency and a shift to higher value-added products. SG&A ratio was 40.5% (prior year 43.6%), R&D ratio 25.8% (prior year 23.3%), indicating R&D front-loading. ROE was -1.7% (prior year -2.0%), improving but negative. Net profit margin -17.9% (prior year -24.4%) × Total Asset Turnover 0.064 (prior year 0.055) × Financial Leverage 1.50 (prior year 1.49): improvement was mainly driven by net profit margin. EBITDA approximated: operating loss ¥-11.4B + depreciation and amortization ¥5.4B = approx. ¥-6.0B, yielding EBITDA margin of about -12.6%. [Cash Quality] Operating CF ¥-9.5B is roughly in line with net loss ¥-8.5B, indicating cash generation remains weak. This is a major improvement from ¥-98.3B a year earlier, but inventory increase ¥-4.4B and other outflows ¥-11.8B weighed on cash. Operating CF / Net Income is negative for both, making formal ratio interpretation difficult, but YoY improvement is substantial. Working capital management saw accounts receivable decrease +¥9.3B (positive), inventory increase -¥4.4B and prepaid expenses/others -¥11.8B (negative). [Investment Efficiency] ROA was -1.1% (prior year -1.3%), improving though negative. ROIC is not computable (negative operating income), but with business assets ~¥600B and operating loss ¥-11.4B, this equates to about -1.9%, suggesting fundamental capital efficiency improvements require a return to profitability. Total asset turnover was 0.064x (prior year 0.055x), mildly improved; composition of cash, goodwill and fixed assets depresses turnover. [Financial Soundness] Equity ratio 66.6% (prior year 66.9%) remains high and stable. Interest-bearing debt ¥163.4B (short-term borrowings ¥26.1B + long-term borrowings ¥137.3B), cash ¥255.5B, net cash approx. ¥92B, net D/E -0.18x, effectively near zero net debt. Current ratio 406% (prior year 166%) markedly improved due to conversion of short-term borrowings to long-term. Goodwill ¥83.7B (16.8% of shareholders' equity) is moderate and impairment risk is manageable.
Cash Flow Analysis
Operating CF was ¥-9.5B (prior year ¥-98.3B), a major improvement from last year's large negative but still negative. Starting from pre-tax quarterly loss ¥-12.0B plus depreciation/amortization ¥5.4B, working capital contributed with decrease in trade receivables +¥9.3B (inflow), inventory increase -¥4.4B, retirement benefit -¥0.0B, and other items -¥11.8B (outflow). Large other outflows were mainly uncollected corporate income taxes ¥-3.9B and decrease in contract liabilities ¥-2.5B; adjustments to advance receipts and prepaid items pressured cash flow. Interest received ¥0.5B, interest paid ¥-0.9B, corporate tax paid ¥-0.0B resulted in operating CF ¥-9.5B. Investing CF was ¥-3.2B, including acquisition of tangible fixed assets ¥-2.7B, acquisition of intangible assets ¥-0.6B, loan recovery +¥0.0B, and others +¥0.2B. Free CF was approx. ¥-12.7B (operating CF -¥9.5B + investing CF -¥3.2B), indicating ongoing outflow. Financing CF was ¥-19.0B, with long-term borrowings +¥164.4B, repayment of long-term borrowings -¥171.0B, installment payments -¥0.5B, borrowing fees -¥1.0B, lease repayments -¥0.9B, and treasury stock acquisition -¥10.0B as principal items. Short-term borrowings reduced substantially from ¥170.4B to ¥26.1B (decrease ¥144.3B), and long-term borrowings increased from 0 to ¥137.3B; net decrease due to refinancing and repayment was approx. ¥16.0B. Foreign exchange effects +¥0.3B; cash and equivalents from opening ¥286.8B to closing ¥255.5B, a decrease of ¥31.3B. Overall, cash decreased due to operating losses and share buybacks, but YoY improvement is significant. Conversion of short-term borrowings to long-term improved financial stability; correcting working capital (inventory normalization and faster collections) will be key to future cash generation.
Quality of Earnings
Current revenue structure is generally recurring with limited one-off items. Against operating loss ¥-11.4B, financial income ¥0.9B and financial expenses ¥1.6B produced net financial expense ¥-0.6B (1.3% of revenue), and other income ¥0.0B / other expenses ¥0.1B summed to a minor ¥-0.1B. Business combination related expenses (intangible asset amortization) were ¥0.2B with limited impact on consolidated operating loss. Transition from ordinary loss ¥-12.2B to profit before tax ¥-12.0B aligned closely aside from equity-method loss ¥-0.0B, and extraordinary items were effectively absent. Corporate tax benefit ¥3.5B resulted from restrained derecognition of deferred tax assets and refunds of prior year provisional payments; net loss ¥-8.5B was partially offset by tax effects. Comprehensive income was ¥-8.5B, matching net loss; other comprehensive income was nil with no non-recurring FX translation or marketable securities valuation impacts. Operating CF ¥-9.5B was nearly equivalent to net loss ¥-8.5B, so profit-loss and cash divergence is small. However, working capital showed AR decrease +¥9.3B (improved collection not included in recurring revenue), inventory increase -¥4.4B and prepaid items -¥11.8B, increasing accruals. Overall, earnings quality is stable on an ordinary basis with few one-offs, but operating CF deficit indicates weak internal cash generation; correcting inventory/prepaid items and margin improvement will determine quality of cash conversion going forward.
Forecasts & Guidance
Company full-year plan: Revenue ¥320.0B, Operating Income ¥46.0B, Net Income ¥30.0B, Dividend ¥0. Q1 results: Revenue ¥47.6B (progress 14.9%), operating loss ¥-11.4B (below plan), net loss ¥-8.5B (below plan), significantly under standard equal-quarter pacing (Q1 = 25%). Main reasons for sluggish revenue progress are assumed to be postponement of Drug Discovery milestone/license income and Q1 Radiopharmaceutical sales below plan. Despite gross margin improvement, operating profit remains negative in Q1 due to front-loaded R&D and losses in Drug Discovery; to achieve full-year profitability, Radiopharmaceutical margin improvement (from 1.8% upward) and multiple milestone recognitions in Drug Discovery are indispensable. To meet the full-year target, average quarterly revenue of approx. ¥91B and operating profit exceeding ¥2.0B per quarter from Q2 onward (or concentrated performance in later quarters) is needed; realization of large deals and accelerated cost reduction are prerequisites. Order backlog / contract liabilities (advance receipts) decreased to ¥7.5B (prior year ¥10.0B), a mildly weak leading indicator. No revision to full-year guidance was announced this quarter; however, given the slow Q1 start, confirmation of progress in Q2 is critical.
Shareholder Returns
Dividend this period ¥0 (prior year ¥0). With continued operating losses, dividends were withheld and the company maintains a full-year dividend plan of ¥0. Meanwhile, treasury stock purchases of ¥10.0B were executed (prior year ¥9.6B), indicating some continuation of shareholder returns as part of capital policy. Free CF was ¥-12.7B (negative), so buybacks were financed from cash balance and borrowings. Payout Ratio is not meaningful under net loss, and Total Return Ratio is also not calculable under negative earnings. Cash balance ¥255.5B is ample, but sustainability of returns while operating CF remains negative is a concern. Resumption of dividends is likely conditioned on return to operating profitability and positive free cash flow. Continued treasury stock purchases signal intent to enhance per-share value, but strengthening business cash generation is key to sustaining return policy.
Risk Factors
-
Concentration risk in Radiopharmaceuticals: Radiopharmaceuticals represent 85.9% of external sales; variability in demand for diagnostic and therapeutic products, disruption in radionuclide supply, regulatory changes, and reimbursement price revisions directly affect performance. Segment operating margin this period is 1.8%—extremely thin—so deteriorations in manufacturing yield or unsuccessful price negotiations pose high downside risk. Limited geographic/product diversification and single-business dependence increase financial volatility.
-
Continued losses and front-loaded investment risk in Drug Discovery: Drug Discovery segment has revenue ¥6.7B versus operating loss ¥-11.9B (margin -177.9%), with heavy front-loaded R&D spending ¥12.3B (25.8% of revenue). Clinical trial delays/failures, difficulties in partnership negotiations, or missed milestones could undermine plan assumptions and jeopardize the full-year operating income target ¥46.0B. Decrease in order backlog / contract liabilities (¥7.5B vs prior year ¥10.0B) is a weak leading indicator; realization of projects from Q2 onward is uncertain.
-
Working capital management and liquidity risk: Inventory ¥36.3B (prior year ¥31.9B, +13.8%) increased faster than revenue, with estimated inventory days ~119 and a lengthening trend. Risk of inventory obsolescence/valuation write-downs and cash tie-up is a concern. Operating CF remains ¥-9.5B and prepaid expenses increased -¥11.8B, accelerating cash outflows. Free CF ¥-12.7B indicates outflow; while cash balance ¥255.5B is ample, ongoing operating deficits and continued buybacks could erode liquidity over time. Short-term borrowings were largely converted to long-term (now ¥26.1B), improving maturity profile, but prolonged operating CF deficits would gradually consume financial flexibility.
Industry Benchmark (Reference — Company Analysis)
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | −23.9% | – | – |
| Net Profit Margin | −17.9% | – | – |
Median industry benchmark data are insufficient for robust comparison, but the company’s operating margin of -23.9% is considered a temporary level for an R&D-first, discovery-oriented company, and progress to profitability will be the inflection point for industry assessment.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 12.6% | – | – |
Revenue growth of +12.6% is solid two-digit growth, but relative industry ranking requires median data. Market expansion in radiopharmaceuticals and progression of discovery partnerships support this growth.
※Source: Company aggregation
Key Points to Watch in the Earnings
-
Gross margin improvement and operating leverage inflection: Gross margin improved to 42.6% (from 34.7%, +7.9pp), evidencing manufacturing efficiency and mix effects. Operating loss narrowed by 16.6%, and with top-line growth and fixed-cost absorption there is a visible roadmap toward profitability. Radiopharmaceutical margin improvement (currently 1.8%) and milestone recognition in Drug Discovery are the primary drivers of future profitability. Monitor quarterly trends in gross margin, SG&A ratio, and the extent to which operating leverage materializes.
-
Improved financial stability and capital allocation flexibility: Large reduction in short-term borrowings (¥170.4B → ¥26.1B) and conversion to long-term borrowings (¥137.3B) significantly reduced maturity mismatch risk; current ratio improved to 406%. Net cash approx. ¥92B and equity ratio 66.6% provide strong financial resilience, allowing continuation of R&D investment alongside buybacks. Although operating CF is negative, the YoY improvement (¥-98.3B → ¥-9.5B) suggests that with working capital correction and margin improvement, a full recovery in cash generation is feasible.
-
Uncertainty in achieving full-year plan and importance of Q2: Q1 revenue progress 14.9% and continued operating loss overshoots standard pacing by over 10pp. To achieve full-year operating income ¥46.0B, quarterly average operating income of over ¥20B is required in later quarters, contingent on multiple milestone recognitions in Drug Discovery and substantial margin improvement in Radiopharmaceuticals. Decline in order backlog / contract liabilities (¥7.5B vs prior year ¥10.0B) is a weak leading indicator; Q2 realization of projects and progress rates will be the trigger for re-evaluating full-year guidance.
This report is an AI-generated earnings analysis document created by analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information aggregated by the company from publicly disclosed financial statements. Investment decisions are your responsibility; please consult experts as needed before making investment decisions.
AI Financial Analysis
Executive Summary
PeptiDream’s FY2026 Q1 result showed a meaningful narrowing of losses and improved gross profitability, but the quarterly result remains far below the profitability implied by full-year guidance. Revenue rose 12.6% year on year to ¥4.76bn. Gross profit increased 38.1% to ¥2.03bn as cost of sales declined 1.0% despite higher revenue. Consequently, gross margin expanded to 42.6% from 34.7%, an improvement of approximately 790 basis points. Operating loss narrowed by ¥227mn to ¥1.14bn from a ¥1.37bn loss. Net loss narrowed by ¥178mn to ¥855mn, and basic EPS improved to negative ¥6.62 from negative ¥7.97. The operating margin nevertheless remained deeply negative at 23.9%. The drug discovery business remained loss-making, although its segment loss narrowed to ¥1.19bn from ¥1.43bn. The radiopharmaceutical business was the core earnings contributor, generating segment profit of ¥75mn, although this was down 10.7% year on year. R&D expense increased 24.6% to ¥1.23bn, outpacing revenue growth and reflecting continued investment in the pipeline and platform. Operating cash flow was negative ¥946mn, broadly aligned with the net loss of ¥855mn; the OCF-to-net-income ratio of 1.11x therefore indicates that the loss was largely cash-backed rather than driven by adverse accruals. Free cash flow was negative ¥1.27bn after capital expenditure. Cash declined ¥3.13bn during the quarter, with operating cash outflow, investment spending, and ¥998mn of share repurchases all contributing. The balance sheet remains well capitalized, with an equity ratio of 66.6%, cash of ¥25.55bn, and debt-to-equity of 0.50x. Management retained FY2026 guidance for revenue of ¥32.0bn, operating income of ¥4.6bn, and profit attributable to owners of ¥3.0bn. Q1 revenue represents only 14.9% of the full-year revenue target, while the operating result is a loss versus the full-year operating-profit target; this indicates that delivery depends heavily on substantially stronger subsequent quarters, likely including milestone, licensing, and/or partnership-related revenue. The key investment issue is whether the gross-margin recovery and radiopharmaceutical revenue expansion can be converted into operating leverage while maintaining the elevated pace of R&D investment.
Profitability Analysis
Annualized DuPont ROE was negative 6.9%, comprising a negative 17.9% net profit margin, 0.255x asset turnover, and 1.50x financial leverage. The negative net margin is the principal driver of the negative ROE, rather than excessive financial leverage. Annualized asset turnover of 0.255x is modest, reflecting a large asset base relative to the current revenue run-rate, including ¥18.82bn of PPE, ¥8.37bn of goodwill, and substantial cash. Financial leverage of 1.50x is moderate and does not suggest that balance-sheet leverage is amplifying shareholder-return volatility materially. Gross-margin improvement was the most favorable profitability movement: revenue growth of 12.6% combined with a 1.0% decline in cost of sales lifted gross profit by 38.1%. However, this was insufficient to cover operating costs. R&D expense increased 24.6% to ¥1.23bn, while SG&A excluding separately disclosed R&D rose 4.7% to ¥1.93bn. Aggregate operating expenses including R&D increased approximately 15.3%, faster than revenue, limiting operating leverage despite the gross-margin gain. EBIT margin was negative 23.9%, triggering the low-operating-efficiency alert and remaining well below the 5% minimum profitability benchmark. The root cause is that current gross profit of ¥2.03bn does not yet absorb R&D and corporate operating costs. This is consistent with an R&D-intensive pharmaceutical and drug-discovery model, but the persistence of a large drug-discovery segment loss means that profitability depends on converting platform activity into higher-margin milestones, licenses, or downstream economics. Annualized ROIC of negative 4.9% also triggers the capital-efficiency alert, showing that the invested capital base is not currently earning an adequate return. The improvement in operating loss is encouraging, but sustained improvement requires gross-profit expansion to exceed the growth in pipeline investment and fixed operating costs.
Growth Assessment
Revenue growth was led by both reported businesses. Drug discovery revenue increased 64.6% year on year to ¥670mn, while radiopharmaceutical revenue increased 7.0% to ¥4.09bn. Radiopharmaceuticals accounted for 85.9% of consolidated external revenue and is therefore the core business by both revenue and operating-income contribution. Its segment profit of ¥75mn implies a positive segment margin of approximately 1.8% on external revenue, compared with the drug-discovery segment loss of ¥1.19bn and a negative margin of approximately 178.0%. The drug-discovery loss narrowed 16.5% year on year, but its revenue base remains too small to fund its R&D burden. Group gross-profit growth materially exceeded sales growth, suggesting favorable product or revenue mix and/or improved production economics in the quarter. Inventory increased ¥435mn during the quarter to ¥3.63bn, which may reflect preparation for radiopharmaceutical demand but requires conversion into sales to validate growth quality. FY2026 guidance implies revenue of ¥32.0bn, operating income of ¥4.6bn, and net income of ¥3.0bn. Q1 progress against the revenue target is 14.9%, 10.1 percentage points below the standard 25% first-quarter run rate. Q1 operating income progress is negative because the company recorded a ¥1.14bn loss against the ¥4.6bn full-year profit target. Given the business model, quarterly revenue may be affected by the timing of research fees, milestones, and licensing income, but the retained forecast embeds a substantial second-half earnings concentration. No forecast revision was announced. The near-term growth test is whether the higher-margin revenue profile can continue while radiopharmaceutical profitability recovers and drug-discovery losses continue to narrow.
Financial Health
Financial health is sound from a liquidity and capitalization perspective. Current assets were ¥36.72bn against current liabilities of ¥9.04bn, producing a calculated current ratio of approximately 4.06x and working capital of approximately ¥27.68bn. This is comfortably above the 1.0x warning threshold and indicates no evident near-term maturity mismatch. Cash and equivalents of ¥25.55bn covered short-term borrowings of ¥2.61bn by approximately 9.8x. The quality alert identifying cash-to-short-term-debt of 0.00x is inconsistent with the reported cash and short-term borrowing balances; based on the disclosed amounts, liquidity is strong rather than stressed. Total interest-bearing debt was ¥16.34bn, consisting of ¥2.61bn short-term and ¥13.73bn long-term borrowings. Debt-to-equity was 0.50x and debt-to-capital was 24.7%, both within conservative benchmark ranges and well below the D/E warning level of 2.0x. The refinancing of ¥17.10bn of long-term debt repayments with ¥16.44bn of new long-term borrowings reduced short-term loans from ¥17.04bn at FY2025 year-end to ¥2.61bn at Q1 end, while increasing long-term debt to ¥13.73bn. This refinancing materially improved the debt-maturity profile by moving obligations away from the short term. Finance costs of ¥155mn exceeded finance income of ¥95mn, and negative EBIT means earnings-based interest coverage is weak; therefore, interest servicing currently relies on liquidity and future operating improvement rather than operating profit. Goodwill was ¥8.37bn, equal to 16.8% of equity and 11.2% of assets, remaining within the healthy goodwill-to-equity benchmark of below 30%. Deferred tax assets totaled ¥6.56bn, representing 13.2% of equity, making the pace of future taxable-profit generation relevant to the recoverability of this asset. Treasury stock increased by ¥956mn, or 50.4%, to negative ¥2.85bn following share repurchases; this reduced equity alongside the quarterly loss.
Notable B/S Changes
Short-term loans: -¥14.43bn (-84.7%) to ¥2.61bn - debt was refinanced toward long-term borrowings, materially reducing short-term refinancing pressure. Long-term loans: +¥13.73bn from no year-end noncurrent borrowing balance - reflects the refinancing structure and shifts debt maturity into noncurrent liabilities. Treasury stock: -¥0.96bn (-50.4%) to -¥2.85bn - Q1 share repurchases reduced equity and consumed cash despite the quarterly net loss. Cash and equivalents: -¥3.13bn (-10.9%) from ¥28.68bn at FY2025 year-end to ¥25.55bn - driven by negative operating and investing cash flow, net debt refinancing outflow, and buybacks. Inventories: +¥0.44bn (+13.6%) to ¥3.63bn - contributed to negative operating cash flow and supports the elevated 121-day annualized inventory metric. Other current assets: +¥1.05bn (+90.9%) to ¥2.20bn - a material increase within current assets that should be monitored for cash-conversion implications.
Cash Flow Quality
Operating cash flow was negative ¥946mn, compared with a net loss of ¥855mn. The OCF-to-net-income ratio was 1.11x, which is above the 1.0x quality benchmark; in the context of a loss, this means the accounting loss was broadly reflected in cash flow rather than being worsened by poor accrual conversion. The accruals ratio was 0.1%, also consistent with limited accrual distortion. Working-capital movements were mixed. A ¥932mn reduction in receivables and a ¥379mn increase in payables supported operating cash flow. These favorable movements were more than offset by a ¥435mn inventory increase and ¥1.18bn of other working-capital outflows. The receivables reduction does not indicate aggressive revenue recognition in the quarter, but continued collection performance remains important given the annualized DSO alert of 95 days. A 95-day DSO exceeds the 60-day alert threshold and increases the sensitivity of operating cash flow to collection timing, particularly if revenue includes large counterparties or milestone receivables. Inventory days were 121 on an annualized basis, above both the 90-day and 60-day alert thresholds. The root cause is inventory of ¥3.63bn relative to annualized Q1 cost of sales of approximately ¥10.95bn. For a radiopharmaceutical operation, inventory can reflect production and supply-chain requirements, but the quarter’s ¥435mn build-up raises the risk of cash being tied up in stock and requires monitoring for turnover, obsolescence, and demand conversion. Free cash flow was negative ¥1.27bn after ¥274mn of capital expenditures. The negative free cash flow is manageable relative to ¥25.55bn of cash, but it is not self-funding if sustained alongside buybacks and debt service. Cash decreased ¥3.13bn in Q1, including ¥998mn of treasury-share purchases. Cash conversion should improve only if gross-margin gains translate into operating profitability and inventory growth moderates.
Dividend Sustainability
No dividend payment or FY2026 dividend per share is indicated, and the full-year dividend forecast is ¥0.0 per share. Accordingly, a dividend payout ratio is not applicable. The company instead deployed ¥998mn for share repurchases in Q1. Because the company reported a net loss and negative free cash flow, a total return ratio is not meaningful for the quarter. The buyback was funded from the company’s substantial cash balance rather than current-period earnings or free cash flow. With cash of ¥25.55bn and D/E of 0.50x, the immediate funding capacity for capital returns is solid. However, recurring capital returns would be better supported by a return to positive operating cash flow and free cash flow, particularly while R&D spending is rising and the company is maintaining a meaningful debt balance. The absence of a dividend reduces fixed shareholder-distribution obligations during the investment and earnings-recovery phase.
Risk Assessment
Business risks include High priority: The drug-discovery business remained loss-making at negative ¥1.19bn despite revenue growth to ¥670mn. The business case depends on successful conversion of PDPS-related research, licensing, strategic partnerships, and pipeline advancement into larger and recurring economics., High priority: The retained full-year forecast requires a sharp improvement after Q1, which delivered a ¥1.14bn operating loss versus a ¥4.6bn full-year operating-profit target. Timing variability in licensing, milestone, collaborative-research, and radiopharmaceutical revenue can create significant quarterly earnings volatility., High priority: Pharmaceutical R&D carries clinical, regulatory, partnership, and commercialization risk. Increased R&D expenditure of ¥1.23bn raises the financial exposure to delays or unsuccessful development outcomes., Medium priority: The radiopharmaceutical segment generated only ¥75mn of profit on ¥4.09bn of revenue, down from ¥84mn a year earlier. Its slim margin leaves earnings sensitive to manufacturing costs, capacity utilization, reimbursement conditions, product mix, and supply-chain execution., Medium priority: Annualized DSO of 95 days exceeds the 60-day threshold. Collection delays could pressure operating cash flow even if reported revenue continues to grow., Medium priority: Annualized inventory days of 121 exceed both alert thresholds. The ¥435mn quarterly inventory build could lead to additional cash consumption or inventory valuation risk if demand does not materialize as expected..
Financial risks include Medium priority: EBIT was negative ¥1.14bn while finance costs were ¥155mn, so operating earnings do not cover interest expense. Liquidity currently mitigates this risk, but a prolonged operating-loss period would increase dependence on the cash balance., Medium priority: Free cash flow was negative ¥1.27bn and total cash declined ¥3.13bn during Q1. Continued operating losses, capex, debt costs, and buybacks would reduce liquidity over time., Medium priority: Deferred tax assets of ¥6.56bn are material relative to equity. Their value depends on the generation of sufficient future taxable income., Low priority: Goodwill of ¥8.37bn equals 16.8% of equity, below the elevated-risk threshold, but remains exposed to impairment if acquired-business cash-flow expectations weaken..
Key concerns include The LOW_OPERATING_EFFICIENCY alert is valid: EBIT margin was negative 23.9%, caused by operating costs and R&D exceeding gross profit. The gross-margin recovery is favorable, but a sustained path to operating leverage is required., The CAPITAL_EFFICIENCY alert is valid: annualized ROIC was negative 4.9%, indicating that the current asset and invested-capital base is not yet producing adequate operating returns., The HIGH_RECEIVABLE_DAYS alert is valid at 95 days. It elevates cash-conversion risk and should be assessed together with future receivable trends and collection timing., Both HIGH_INVENTORY_DAYS alerts are valid: 121 days is elevated against 90-day and 60-day thresholds. This is a material working-capital and inventory-realization monitoring item., The LIQUIDITY_STRESS alert is not supported by the reported balances: cash of ¥25.55bn was approximately 9.8x short-term borrowings of ¥2.61bn, and the calculated current ratio was approximately 4.06x. The capital structure is not currently liquidity stressed..
Investment Implications
Key takeaways include Revenue growth of 12.6% and a 790bp gross-margin expansion demonstrate improved Q1 operating economics., Loss narrowing was meaningful, but the negative 23.9% operating margin confirms that the group has not yet reached scale sufficient to absorb R&D and operating costs., Radiopharmaceuticals are the core earnings contributor, while drug discovery remains the principal source of operating losses despite improving revenue and a smaller segment loss., Liquidity is strong after the refinancing-driven shift from short-term to long-term debt, with cash of ¥25.55bn, a calculated current ratio of 4.06x, and D/E of 0.50x., Full-year guidance embeds substantial back-end loading, making the timing and scale of revenue realization in future quarters the central earnings variable., Negative free cash flow and elevated receivable and inventory days make working-capital discipline important despite the strong cash position..
Metrics to watch include Quarterly revenue and segment profit in the radiopharmaceutical business, Drug-discovery segment loss and the relationship between R&D expense growth and platform-related revenue, Gross margin versus aggregate SG&A and R&D growth, Progress toward FY2026 guidance: revenue ¥32.0bn, operating income ¥4.6bn, and net income ¥3.0bn, Operating cash flow, free cash flow, cash balance, and the pace of share repurchases, Receivable days, inventory days, inventory balances, and payables trends, Interest expense and the pace at which operating profit restores interest-servicing capacity, Deferred-tax-asset recoverability and goodwill impairment indicators.
Regarding relative positioning, Relative to a mature profitable pharmaceutical company, PeptiDream currently has weaker margins and capital efficiency because it is funding significant R&D while its drug-discovery business remains loss-making. Relative to earlier-stage biotechnology companies, it has a more substantial revenue base, a profitable radiopharmaceutical segment, a 66.6% equity ratio, and considerable cash liquidity. Its valuation-relevant operating profile is therefore likely to be driven by the credibility of converting platform and radiopharmaceutical growth into durable operating profit rather than by current-period net earnings.